What JW Holdings does

JW Holdings Corporation is a Korean healthcare holding company established in 1945 and headquartered in Gwacheon-si, South Korea (KOSPI: 096760). It operates a multi-subsidiary structure spanning prescription and OTC pharmaceuticals, IV solutions and parenteral nutrition, medical imaging devices, consumer healthcare, and diagnostic reagents, with manufacturing assets concentrated in seven South Korean plants and overseas sales subsidiaries in the Philippines and Vietnam.

The group generates revenue through four streams: pharmaceutical manufacturing and sales (domestic and export), management services and royalties from subsidiaries, technology export and licensing to international partners (Baxter, Sawai, Nichiiko, Greenpine, Simcere, LEO Pharma, Kissei, Shandong Luoxin), and medical device sales. Proprietary technology platforms include the JWELRY peptide-mimetic compound library, CLOVER omics data platform, SMEDDS solubilization technology, Non-PVC IV film technology (produced in-house via JW Chemitown), and three-chamber TPN systems. The R&D pipeline contains 31 compounds across oncology, immunology, metabolic diseases, and rare disorders, with R&D intensity above 14% of revenue.

JW exports to 50+ countries and reports consolidated 2024 sales of KRW 719,376 million and operating income of KRW 82,488 million, with Q3 2025 operating profit up 38.4% year-over-year. Recent strategic activity centers on late-stage pipeline execution (Epaminurad Phase 3 completion, JW0061 IND approval, DDC-02 and rare pediatric candidates), the in-licensing of a bi-weekly GLP-1 obesity drug from Gan & Lee (April 2026), and inorganic expansion via the acquisition of bio/healthcare VC firm Solidus Investment (March 2026).

Name

JW Holdings

Legal name

JW홀딩스 주식회사 (JW Holdings Corporation)

Website

https://jw-holdings.co.kr

Company type

Private

Founded year

1945

Operating status

Operating

Headcount range

101–250 employees

Short description

JW Holdings is a Korean healthcare holding company operating subsidiaries in pharmaceuticals, IV solutions, medical devices, and consumer health, manufacturing and exporting to 50+ countries with an R&D pipeline spanning oncology, immunology, and metabolic diseases.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• Medical devices
• IV solutions
• Consumer healthcare

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Revenue from manufacturing and selling pharmaceutical products including prescription drugs, OTC products, and medical devices through domestic and export channels
2. Management Services and Royalties: Profits from management services, subsidiaries' equity interest, brand royalties, and service fees from subsidiary companies
3. Technology Export and Licensing: Revenue from licensing out proprietary technologies and drug candidates to international partners
4. Medical Device Sales: Sales of medical devices including infant care systems, operating room equipment, diagnostic equipment, and sterilization equipment

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

JW Holdings is a South Korean healthcare holding company that, through its subsidiaries, manufactures and sells prescription pharmaceuticals, over-the-counter drugs, IV solutions, medical devices, consumer healthcare products, and IV solution manufacturing equipment. Its flagship subsidiary JW Pharmaceutical develops original drugs including TPN solutions (Combiflex, Winuf), cardiovascular drugs (Livalo), carbapenem antibiotics (Prepenem, Pospenem), and a 31-compound R&D pipeline spanning oncology, immunology, metabolic, and rare diseases. JW Medical produces diagnostic imaging equipment, JW Life Science specializes in IV solutions with Non-PVC containers, and JW Living Healthcare markets consumer health products.

Product overview

JW Holdings is a Korean healthcare group comprising multiple subsidiaries offering pharmaceuticals, medical devices, consumer healthcare products, and plant engineering equipment. JW Pharmaceutical (JW중외제약) focuses on original drug development including TPN solutions (Combiflex, Winuf), cardiovascular drugs (Livalo), antibiotics (Prepenem, Pospenem), and a diverse pipeline spanning oncology, immunology, metabolic diseases, and rare disorders. JW Medical produces diagnostic imaging equipment and surgical devices. JW Life Science specializes in IV solutions and non-PVC containers. The consumer healthcare division offers wound care (Hi-mom Band), pain management (Pain Angel), and eye care products. Plant engineering includes STYER brand IV solution manufacturing equipment. The group also maintains diagnostics programs including sepsis and pancreatic cancer biomarkers.

Differentiator

Problem solved

Functional benefit

Brands

• JW중외제약 (JW Pharmaceutical): Core pharmaceutical company leading Korea's therapeutic drug market with a robust original drug pipeline and global R&D network for innovative new drug development.
• JW신약 (JW Shinyak)
• JW생명과학 (JW Life Science)
• JW메디칼 (JW Medical)
• JW생활건강 (JW Living Healthcare)
• JW바아오사이언스 (JW Bioscience)
• STYER
• Hi-mom Band
• 페인엔젤 (Pain Angel)
• 프리엔즈 점안액 / I-Angel (Frenzeye/I-Angel Eye Drops)

Products and services

• Combiflex Lipid Central Three-chamber TPN (Total Parenteral Nutrition) solution providing water, electrolytes, amino acids, calories, and essential fatty acids for patients requiring intravenous nutrition support.
• Combiflex Lipid Peri Perioperative TPN solution for patients unable to receive oral or enteral nutrition.
• Combiflex MCT Peri TPN solution containing medium-chain triglycerides for improved fat absorption in parenteral nutrition.
• Winuf Three-chamber bag parenteral nutrition containing high-content purified fish oil with omega-3, providing anti-inflammatory effects and nutritional balance. Licensed to Baxter in USA and Shandong Luoxin in China.
• Ipision 20% Fat emulsion providing energy and essential fatty acids as part of parenteral nutrition regimens.
• Freamine Amino acid solutions (8.5% and 10%) for hypoproteinemia, malnutrition, and pre/post surgical nutrition support.
• Livalo (Pitavastatin) HMG-CoA reductase inhibitor for primary hypercholesterolemia and dyslipidemia, proven to minimize diabetes risk.
• Prepenem Carbapenem antibiotic (Imipenem) effective against gram-negative and gram-positive bacteria including Pseudomonas aeruginosa.
• Pospenem Carbapenem antibiotic (Meropenem) with broad-spectrum activity against various bacterial infections.
• JW-i3000 Infant Incubator Advanced infant care system with 10.1-inch full touch screen control, dual skin sensors, and cassette-type water reservoir for neonatal intensive care.
• JW-W2000 Infant Warmer Advanced infant warming device with dual skin sensors, tilting mattress, and integrated phototherapy options for neonatal care.
• JW-PU1000 LED Phototherapy Unit LED phototherapy device for newborn jaundice treatment with height adjustment and variable housing tilt.
• Honeylux LED Surgical Light LED operating lights providing up to 160,000 lux illumination with adjustable color temperature for various surgical procedures.
• JW-T7000 Electro-hydraulic Operating Table Multi-purpose electro-hydraulic surgical table with wireless/wired remote control and 270kg loading capacity.
• JW-G2000 Gynecological Examining Table Electric gynecological examination table with hand remote and foot switch control for examination and sonography positions.
• VIDIX II Digital X-ray Direct type digital radiography system with auto-tracking and synchronized functions for diagnostic imaging.
• STYER FFS Machine Forming-Filling-Sealing machine for IV solution production, handling 100mL to 1L bags for single and multi-chamber solutions.
• STYER Over Wrap Machine Overwrapping equipment for 1L to 5L mono chamber bags and multi-chamber IV solution containers.
• STYER IV Bag Making Machine Equipment for manufacturing empty IV bags including mono and multi-chamber configurations.
• Hi-mom Band Premium Hydrocolloid wound care band containing aloe vera for wound healing and scar minimization.
• Hi-mom Burn Spray Hydrogel-based first aid spray for burn emergency treatment and cooling relief.
• Pain Angel NSAID pain relief products (Sen/Pro/Evu variants) for arthritis, osteoarthritis, and pain management.
• I-Angel Eye Drops Artificial tears containing sodium carboxymethyl cellulose for dry eye relief and comfort.
• Hemlibra (Emicizumab) Bispecific monoclonal antibody for routine prophylaxis in hemophilia A patients with or without factor VIII inhibitors; received rare drug designation and market sales permit.
• Mobilia (Plerixafor) CXCR4 antagonist for hematopoietic stem cell mobilization in non-Hodgkin lymphoma and multiple myeloma patients.
• URC102 / Epaminurad URAT1 inhibitor for gout treatment with reduced renal elimination of uric acid; Phase 3 trial completed. Licensed to Simcere (China).

Quantifiable outcome

• Q3 2025 operating profit increased 38.4% year-over-year to 5 billion won
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Simcere PharmaceuticalcoreTechnology or Integration · 1 October 2019License out agreement for URC102 gout treatment drug. Technology export worth 80 billion won.
• ArgonautminorStrategic or Co-development Partner · 1 October 2018Strategic investment agreement for next-generation anticancer drug based on epigenetics
• LEO PharmacoreStrategic or Co-development Partner · 1 August 2018License out agreement for atopic dermatitis drug candidate JW1601. Technology export worth 450 billion won. Recognized as 'Open Innovation Case' at 60th anniversary of Korea-Denmark diplomatic relations.
• A*STAR (Singapore)minorStrategic or Co-development Partner · 1 July 2018Collaboration research agreement on new drugs between C&C Research Laboratories and A*STAR. Development of immunological disease and anticancer drugs with four research institutes.
• LeoparmminorStrategic or Co-development Partner · 1 May 2018Open innovation partnership in skin disease field for 60th anniversary of Korean-Denmark diplomatic relations
• BaxtercoreTechnology or IntegrationLicense out agreement for Winuf (3-Chamber I.V. solution) technology in USA market. Joint development of next-generation nutrient sap.
• SawaicoreTechnology or IntegrationLicense out agreement for Itraconazole SD product in Japan market
• NichiikocoreTechnology or IntegrationLicense out agreement for Itraconazole tablet product in Japan market
• Greenpine (China)coreTechnology or IntegrationLicense out agreement for Prepenem injection and Q-Roxin tablet products in China
• Shandong Luoxin Pharmaceutical GroupcoreTechnology or IntegrationExclusive technology export and provision agreement for Winuf in China

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Baxter International: Global IV solutions, parenteral nutrition, and medical devices incumbent that licenses JW's three-chamber TPN Winuf technology for the US market. Comparable on IV/nutrition portfolio scale and acts as a global benchmark for JW Life Science's technology value.
• B. Braun: Global leader in IV solutions, infusion therapy, and parenteral nutrition devices with established three-chamber TPN systems. Represents the global standard JW Life Science competes against in TPN and acts as a relevant scale benchmark.

Emerging players

• Celltrion: Korean biosimilars leader that scaled from a domestic base to global markets via licensing — a useful growth-archetype benchmark for JW Pharmaceutical's ambition to internationalize its proprietary and biosimilar assets.

Direct peers

• GC Biopharma: Korean-listed biopharmaceutical company producing vaccines, plasma-derived therapies, and specialty biologics. Comparable in scale, R&D investment intensity, and pipeline ambition, though more weighted to biologicals than JW's small-molecule focus.
• Chong Kun Dang (CKD): Korean pharmaceutical manufacturer specializing in prescription drugs, APIs, and biosimilars with growing export presence. Closely comparable to JW Pharmaceutical in therapeutic portfolio (metabolic, cardiovascular) and pipeline structure.
• Dong-A ST: Mid-sized Korean pharmaceutical firm with branded prescription drugs, biologics (DA-3801, teriparatide biosimilar), and consumer health brands. Comparable scale, therapeutic focus on metabolic and rare diseases, and export orientation.
• Yuhan Corporation: One of Korea's largest integrated pharmaceutical companies with branded prescription drugs, OTC products, consumer healthcare, and a global licensing footprint — directly comparable to JW Holdings across business mix, Korean-market positioning, and export channels.
• Daewoong Pharmaceutical: Korean pharmaceutical group with branded prescription drugs, OTC consumer healthcare, and medical device subsidiaries. Competes with JW in Korean hospital/clinic channels and has comparable international licensing activity in Southeast Asia.
• Ildong Pharmaceutical: Korean pharmaceutical company with prescription drugs, OTC brands, and health functional foods — a near-analog of JW's diversified prescription-plus-consumer-health model across similar Korean and Asian export channels.
• Hanmi Pharmaceutical: Korean R&D-intensive pharma with a deep specialty pipeline (diabetes, oncology, immunology) and extensive global out-licensing history (Sanofi, Eli Lilly, Boehringer Ingelheim) — closely comparable to JW Pharmaceutical's pipeline-led, licensing-driven growth model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jw-holdings

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Holdings